Genprex moves closer to clinical testing of its diabetes gene therapy through a new manufacturing partnership, amid ongoing efforts to build its pipeline despite high investor caution.
Genprex has moved a step closer to advancing its diabetes gene therapy programme after striking a manufacturing collaboration with a US contract development and manufacturing organisation, a deal aimed at securing facilities that meet current good manufacturing practice standards for the production of its adeno-associated virus-based candidates. The company said the work will support preclinical studies intended to prepare the programme for clinical testing.
The latest agreement adds to a series of recent efforts by Genprex to build out its diabetes pipeline. In February, the company said it had updated and consolidated its existing licensing arrangements with the University of Pittsburgh into a new exclusive agreement covering multiple technologies linked to a gene therapy for both type 1 and type 2 diabetes. At the same time, Genprex formed a wholly owned subsidiary, Convergen Biotech, to focus on the programme’s development.
The pipeline itself remains at an early stage, but it has shown signs of momentum. Collaborators presented positive preclinical data on Genprex’s diabetes gene therapy for type 2 diabetes at the 2026 annual meeting of the American Society of Gene and Cell Therapy, according to a BioSpace press release. The company has also said it is exploring next-generation delivery approaches, including non-viral lipid nanoparticle systems, which could in theory allow repeat dosing, a potential advantage in chronic diseases such as diabetes.
Even so, investors continue to view the stock as highly speculative. GuruFocus said Genprex has no reported revenue, making its price-to-sales ratio effectively meaningless in conventional valuation terms, while its GF Score of 33 out of 100 points to weak profitability and growth despite relatively solid financial strength. Insider tracking data cited by the service showed no recent insider buying and some selling over the past year, a pattern that may temper confidence in the near-term outlook.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
